×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VIR – vir biotechnology, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VIR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
10:24 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
11/20
08:07 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
11/18
09:19 pm
vir
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program [Yahoo! Finance]
Medium
Report
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program [Yahoo! Finance]
11/18
09:15 pm
vir
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Medium
Report
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
11/18
04:11 pm
vir
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency [Yahoo! Finance]
Low
Report
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency [Yahoo! Finance]
11/18
04:05 pm
vir
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Low
Report
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
11/15
01:44 pm
vir
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? [Yahoo! Finance]
Low
Report
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? [Yahoo! Finance]
11/15
11:04 am
vir
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting [Yahoo! Finance]
Low
Report
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
01:36 pm
vir
Form 4 Vir Biotechnology, Inc. For: Nov 15 Filed by: O'Byrne Jason
Low
Report
Form 4 Vir Biotechnology, Inc. For: Nov 15 Filed by: O'Byrne Jason
11/7
07:21 pm
vir
Form 4 Vir Biotechnology, Inc. For: Nov 06 Filed by: de Verneuil Vanina
Medium
Report
Form 4 Vir Biotechnology, Inc. For: Nov 06 Filed by: de Verneuil Vanina
11/6
04:56 pm
vir
Form 144 Vir Biotechnology, Inc. Filed by: de Verneuil Vanina
Medium
Report
Form 144 Vir Biotechnology, Inc. Filed by: de Verneuil Vanina
11/5
05:52 pm
vir
Form 4 Vir Biotechnology, Inc. For: Nov 01 Filed by: de Verneuil Vanina
Medium
Report
Form 4 Vir Biotechnology, Inc. For: Nov 01 Filed by: de Verneuil Vanina
11/5
04:24 pm
vir
Form 144 Vir Biotechnology, Inc. Filed by: de Verneuil Vanina
Medium
Report
Form 144 Vir Biotechnology, Inc. Filed by: de Verneuil Vanina
11/4
04:10 pm
vir
Form 10-Q Vir Biotechnology, Inc. For: Sep 30
Medium
Report
Form 10-Q Vir Biotechnology, Inc. For: Sep 30
10/31
04:22 pm
vir
Form 8-K Vir Biotechnology, Inc. For: Oct 31
High
Report
Form 8-K Vir Biotechnology, Inc. For: Oct 31
10/24
04:26 pm
vir
Form 4 Vir Biotechnology, Inc. For: Oct 23 Filed by: SCANGOS GEORGE A
Low
Report
Form 4 Vir Biotechnology, Inc. For: Oct 23 Filed by: SCANGOS GEORGE A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/25
CDC Issues Warnings on Virus; Markets Take Hit: Virus Update [Yahoo! Finance News]
61.4%
2/27 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. 58.5%
3/13 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. 21.3%
4/6 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions 21.1%
3/13 Eli Lilly CEO aims to start testing coronavirus cure 'this summer' [CNBC] 14.1%
2/25 CDC Tells Americans to Start Readying for Outbreak: Virus Update [Yahoo! Finance News] 12.9%
1/15 Vir Biotechnology (VIR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] 12.5%
3/10 Vir Biotechnology to Present at Barclays Global Healthcare Conference 10.0%
3/26 Q4/2019 12/31/2019 EPS -0.710 ZacksConsensus -0.470 ActVsEst (0.240) - Miss 7.2%
10/18 Form 4 Vir Biotechnology, Inc. For: Oct 16 Filed by: Fullerton Management Pte Ltd 5.5%
2/27 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. 58.5%
3/13 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. 21.3%
4/6 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions 21.1%
3/13 Eli Lilly CEO aims to start testing coronavirus cure 'this summer' [CNBC] 14.1%
2/25 CDC Tells Americans to Start Readying for Outbreak: Virus Update [Yahoo! Finance News] 12.9%
1/15 Vir Biotechnology (VIR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] 12.5%
3/10 Vir Biotechnology to Present at Barclays Global Healthcare Conference 10.0%
3/26 Q4/2019 12/31/2019 EPS -0.710 ZacksConsensus -0.470 ActVsEst (0.240) - Miss 7.2%
10/18 Form 4 Vir Biotechnology, Inc. For: Oct 16 Filed by: Fullerton Management Pte Ltd 5.5%
TOP News Decliners
2/28
Trending Ticker: VIR Surges as Coronavirus fears persist [Yahoo! Finance News]
-35.9%
3/9 Form 8-K Vir Biotechnology, Inc. For: Mar 03 -22.1%
4/7 Biotechs Working Closely & Feverishly With CDC for COVID-19 Vaccine Development -14.4%
3/6 Why Was Vir Biotechnology Up 74% in February? [The Motley Fool] -14.2%
10/10 Form 3 Vir Biotechnology, Inc. For: Oct 10 Filed by: Platinum International Investment Holding RSC Ltd -13.2%
4/8 Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 -11.2%
3/19 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. -10.8%
2/12 Form 8-K Vir Biotechnology, Inc. For: Feb 12 -10.2%
3/25 Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19 -8.5%
4/6 GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln [Reuters] -8.2%
3/9 Form 8-K Vir Biotechnology, Inc. For: Mar 03 -22.1%
4/7 Biotechs Working Closely & Feverishly With CDC for COVID-19 Vaccine Development -14.4%
3/6 Why Was Vir Biotechnology Up 74% in February? [The Motley Fool] -14.2%
10/10 Form 3 Vir Biotechnology, Inc. For: Oct 10 Filed by: Platinum International Investment Holding RSC Ltd -13.2%
4/8 Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 -11.2%
3/19 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. -10.8%
2/12 Form 8-K Vir Biotechnology, Inc. For: Feb 12 -10.2%
3/25 Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19 -8.5%
4/6 GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln [Reuters] -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: